Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 (Mitiperstat) in NASH with Fibrosis
NCT05638737Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing AZD4831 with Placebo (2 arms). Primary endpoint: Relative to Baseline Alanine Aminotransferase at Week 12. Started Oct 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05638737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638737.